Natco Pharma Ltd
NATCOPHARMNatco Pharma Ltd
NATCOPHARMPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
14.31 | 3.75 | 0.55% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
52.96 | 5.94 | 0.54% |
Forecast & Ratings
Detailed Forecastfrom 10 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 840.19 | 1,054.10 | 2,034.10 | 2,225.20 | 2,224.70 | 2,022.40 | 2,155.70 | 2,043.80 | 2,811.70 | 3,943.50 | ||||||||||
Raw Materials | 251.54 | 318.90 | 617.90 | 436.40 | 388.10 | 456.80 | 559.50 | 577.70 | 651.00 | 2,235.20 | ||||||||||
Power & Fuel Cost | 43.24 | 43.70 | 50.50 | 56.20 | 59.60 | 62.40 | 61.10 | 76.40 | 81.90 | |||||||||||
Employee Cost | 136.92 | 179.80 | 243.20 | 325.60 | 355.90 | 375.00 | 414.90 | 444.80 | 486.70 | |||||||||||
Selling & Administrative Expenses | 119.27 | 180.90 | 299.60 | 304.50 | 351.10 | 311.60 | 300.90 | 367.70 | 388.80 | |||||||||||
Operating & Other expenses | 78.49 | 53.40 | 125.60 | 133.70 | 145.00 | 126.60 | 109.50 | 214.70 | 163.10 | |||||||||||
EBITDA | 210.73 | 277.40 | 697.30 | 968.80 | 925.00 | 690.00 | 709.80 | 362.50 | 1,040.20 | 1,708.30 | ||||||||||
Depreciation/Amortization | 47.27 | 50.80 | 54.40 | 66.20 | 81.00 | 99.80 | 116.90 | 142.60 | 163.80 | 172.30 | ||||||||||
PBIT | 163.46 | 226.60 | 642.90 | 902.60 | 844.00 | 590.20 | 592.90 | 219.90 | 876.40 | 1,536.00 | ||||||||||
Interest & Other Items | 31.68 | 22.90 | 18.50 | 15.40 | 19.30 | 21.50 | 13.30 | 17.70 | 14.50 | 15.70 | ||||||||||
PBT | 131.78 | 203.70 | 624.40 | 887.20 | 824.70 | 568.70 | 579.60 | 202.20 | 861.90 | 1,520.30 | ||||||||||
Taxes & Other Items | -2.84 | 46.60 | 138.40 | 191.00 | 180.30 | 107.90 | 138.70 | 32.20 | 146.60 | 242.50 | ||||||||||
Net Income | 134.62 | 157.10 | 486.00 | 696.20 | 644.40 | 460.80 | 440.90 | 170.00 | 715.30 | 1,277.80 | ||||||||||
EPS | 8.12 | 9.23 | 27.89 | 38.81 | 35.09 | 25.26 | 24.20 | 9.32 | 39.22 | 70.03 | ||||||||||
DPS | 1.00 | 1.25 | 6.75 | 8.25 | 6.25 | 6.75 | 5.25 | 4.50 | 5.50 | 9.50 | ||||||||||
Payout ratio | 0.12 | 0.14 | 0.24 | 0.21 | 0.18 | 0.27 | 0.22 | 0.48 | 0.14 | 0.14 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Natco Pharma Ltd | 25.57 | 3.75 | 0.55% |
Sun Pharmaceutical Industries Ltd | 43.04 | 6.15 | 0.76% |
Cipla Ltd | 40.52 | 4.79 | 0.60% |
Dr Reddy's Laboratories Ltd | 22.98 | 4.45 | 0.64% |
Price Comparison
Compare NATCOPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.42%
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.11%
Top 5 Mutual Funds holding Natco Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1488% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/100 (-30) |
Mirae Asset Midcap Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8133% | Percentage of the fund’s portfolio invested in the stock 1.00% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/81 (+2) |
Tata Small Cap Fund-Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4831% | Percentage of the fund’s portfolio invested in the stock 1.37% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 35/56 (+1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
NATCOPHARM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.56%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.61 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 26, 2024
Dividend/Share
₹1.25
Ex DateEx Date
Feb 26, 2024
Cash Dividend
Ex DateEx DateNov 24, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Nov 24, 2023
Cash Dividend
Ex DateEx DateAug 22, 2023
Dividend/Share
₹7.00
Ex DateEx Date
Aug 22, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Feb 21, 2023
Cash Dividend
Ex DateEx DateNov 21, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Nov 21, 2022
News & Opinions
Natco Pharma U.S. arm faces Fresenius complaint over diazepam injection prefilled syringe
1 week ago•The Hindu
Natco Pharma Receives Warning Letter From US Health Regulator
2 weeks ago•Bloomberg Quint
U.S. FDA issues warning letter to Natco over facility near Hyderabad
2 weeks ago•The Hindu
News Video
Natco Pharma Trades Close To Its 52-Week High; Nuvama Expects India Biz To Pick Up In FY25
2 months ago•CNBC-TV18
Natco Pharma Q3 net surges to ₹213 cr. on higher revenue
2 months ago•The Hindu
Natco Pharma Q3 net profit rises over 3-fold to Rs 212.7 crore
2 months ago•Moneycontrol
Natco Pharma Q2 Results Review - Strong Growth On Low Base; Weak Q3 Expected: Nirmal Bang
5 months ago•Bloomberg Quint
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.79%, vs industry avg of 8.36%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.1% to 0.86%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 0.54%, vs industry avg of 9.82%